%0 Journal Article %A Andrew A. Davis %A Wade T. Iams %A David Chan %A Michael S. Oh %A Robert W. Lentz %A Neil Peterman %A Alex Robertson %A Abhik Shah %A Rohith Srivas %A Nicole Lambert %A Peter George %A Becky Wong %A Haleigh Wood %A Jason Close %A Ayse Tezcan %A Ken Nesmith %A Haluk Tezcan %A Young Kwang Chae %T Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors %D 2019 %R 10.1101/19002550 %J medRxiv %P 19002550 %X Purpose Treatment response assessment for patients with advanced solid tumors is complex and existing methods of assessment require greater precision for early disease assessment. Current guidelines rely on imaging, which has limitations such as the long time required before treatment effectiveness can be determined. Serial changes in whole-genome (WG) circulating tumor DNA (ctDNA) were used to detect disease progression early in the treatment course.Methods 97 patients with advanced cancer were enrolled, and blood was collected before and after initiation of a new treatment. Plasma cell-free DNA libraries were prepared for either WG or WG bisulfite sequencing. Longitudinal changes in the fraction of ctDNA were quantified to identify molecular progression or response in a binary manner. Study endpoints were agreement with first follow-up imaging (FUI) and stratification of progression-free survival (PFS).Results Patients with early molecular progression had shorter PFS (n=14; median 62d) compared to others (n=78; median 263d, HR 12.6 [95% confidence interval 5.8-27.3], log-rank P<10−10, 5 excluded from analysis). All cases with molecular progression were confirmed by FUI and molecular progression preceded FUI by a median of 40d. Sensitivity for the assay in identifying clinical progression was 54%, median 24d into treatment and specificity was 100%.Conclusions Molecular progression, based on ctDNA data, detected disease progression for cases on treatment with high specificity approximately 6 weeks before follow-up imaging. This technology may enable early course change to a potentially effective therapy, avoiding side effects and cost associated with cycles of ineffective treatment.Translational Relevance Tools for early assessment of treatment response in advanced solid tumors require refinement. We performed baseline and early serial assessments of WG ctDNA to predict treatment response prior to standard of care clinical and radiographic assessments. Our results demonstrated that the blood-based prediction reliably identified molecular progression, approximately 6 weeks before imaging, with very high specificity and positive predictive value across multiple tumor and treatment types. Patients with molecular progression had significantly shorter progression-free survival compared with non-progressors. In addition, a large quantitative decrease in tumor fraction ratio was associated with significant durable benefit. Collectively, these findings demonstrate that cancer-related changes in the blood precede clinical or imaging changes and may inform changes in management earlier in the treatment course to improve long-term patient outcomes and limit cost.Competing Interest StatementAAD - travel support (Menarini Silicon Biosystems). WTI - advisory board (Genentech), honoraria (Outcomes Insights), investigator meeting (EMD Serono). NP, AR, AS, RS, NL, PG, BW, HW, JC, AT, KN, & HT - employees of and ownership interest in Lexent Bio. AR, AS, KN, & HT - previous employees of and ownership interest in Counsyl. NL - previous employee of and ownership interest in Sequenom. PG - previous employee of and ownership interest in Hologic. YKC - research grant (Abbvie, BMS, Biodesix, Lexent Bio, Freenome), honoraria/advisory board (Roche/Genentech, AstraZeneca, Foundation Medicine, Counsyl, Neogenomics, Guardant Health, Boehringher Ingelheim, Biodesix, Immuneoncia, Lilly Oncology, Merck, Takeda). DC, MSO, & RWL - none.Clinical TrialThis is an observational study without any intervention, registered under NCT02288754.Funding StatementThis study was supported by Lexent Bio, Inc.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData in this manuscript is represented in the methods, results, and supplementary information. %U https://www.medrxiv.org/content/medrxiv/early/2019/08/02/19002550.full.pdf